Drug-induced pancreatitis and exenatide (Byetta)

[1] *ADRAC, 2006, AUST ADV DRUG REACT, V25, P22

[2] Ahmad SR, 2008, NEW ENGL J MED, V358, P1970

[3] [Anonymous], HARRISONS PRINCIPLES

[4] Cure P, 2008, NEW ENGL J MED, V358, P1969, DOI 10.1056/NEJMc0707137

[5] Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 1019 - 1027

[6] Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus [J]. DRUG SAFETY, 2010, 33 (02) : 87 - 100

[7] Drug-induced pancreatitis - An update [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (08) : 709 - 716

[8] U. S. Food and Drug Administration Center for Drug Evaluation and Research, INF HEALTHC PROF EX

[1] *ADRAC, 2006, AUST ADV DRUG REACT, V25, P22

[2] Ahmad SR, 2008, NEW ENGL J MED, V358, P1970

[3] [Anonymous], HARRISONS PRINCIPLES

[4] Cure P, 2008, NEW ENGL J MED, V358, P1969, DOI 10.1056/NEJMc0707137

[5] Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 1019 - 1027

[6] Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus [J]. DRUG SAFETY, 2010, 33 (02) : 87 - 100

[7] Drug-induced pancreatitis - An update [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (08) : 709 - 716

[8] U. S. Food and Drug Administration Center for Drug Evaluation and Research, INF HEALTHC PROF EX